BioSpace News Archive

NextCure, Inc. announced that it will participate in a fireside chat at the JMP Securities Life Sciences Conference in New York City on Wednesday, June 15th at 2 pm ET.

Athenex, Inc. announced the appointment of Darrel P. Cohen, MD, PhD as Chief Medical Officer of Cell Therapy to lead its clinical development, clinical operations, and regulatory affairs functions.

SELLAS Life Sciences Group, Inc. announced encouraging updated clinical data from a Phase 1 investigator-sponsored clinical trial of its lead clinical candidate, galinpepimut-S, combined with the checkpoint inhibitor nivolumab in patients with malignant pleural mesothelioma who were either refractory to or relapsed after at least one line of the standard of care therapy.

CymaBay Therapeutics, Inc. (NASDAQ: CBAY), today announced that multiple seladelpar presentations will be delivered during The International Liver Congress™ 2022 of the European Association for the Study of Liver (EASL) which will be held in London, UK from June 22nd – 26th.

Apexigen, Inc. (“Apexigen”), a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, today announced the appointment of William Duke as Chief Financial Officer, effective immediately.

FX received 510k approval for their new FX V135® platform which includes a new-to-market mini stem humeral component that is set at 135° for both the anatomical and reverse configurations.

Johnson & Johnson published its 2021 Health for Humanity Report, which shares progress against its purpose-driven Health for Humanity 2025 Goals and serves as its annual disclosure on environmental, social and governance performance.

Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference in Rancho Palos Verdes, CA on Wednesday, June 15, 2022 at 11:20 a.m. P.T.

Clearside Biomedical, Inc. announced that Thomas A. Ciulla, M.D., MBA, Chief Medical Officer and Chief Development Officer, will participate in a Fireside Chat at the JMP Securities Life Sciences Conference on Wednesday, June 15, 2022, at 9:30 a.m. Eastern Time, in New York, NY.

Prometheus Biosciences, Inc. (Nasdaq: RXDX), a biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases, today announced an enrollment update on the APOLLO-CD and ARTEMIS-UC trials.